Crunching the numbers for ELVN... Refresh in a moment for the full analysis.
Enliven Therapeutics, Inc. (ELVN)
mixed
$45.32
Updated: 2026-04-13
46
TradeApes Score
hold
Financial Strength
60
Healthy
Operating Trend
40
Weak
Valuation
40
Weak
Capital Allocation
30
Weak
Risk
65
Healthy
Key Findings
+
Low leverage — net debt/EBITDA below 1×
−
Significant dilution — share count up more than 5% year over year
See the full analysis
Quarterly financials, DCF valuation model, Watchlist, and Stock Screener.
Add to Watchlist
Scores and valuations are model outputs, not investment advice. TradeApes does not provide financial, tax, or investment advice.